KIT and gastrointestinal stromal tumor: Although not through the blocking of Abl, imatinib is also approved for gastrointestinal stromal tumours (GISTs), characterized by activating mutations in receptor tyrosine kinase genes (most commonly in c-KIT) that increase the proliferation of tumour cells [62].